Neovasc Inc.

Canaccord Genuity is pleased to announce that on February 3, 2015, it completed an underwritten public offering of common stock for Neovasc Inc. The Company issued a total of 10,415,000 shares of common stock at a price of $7.19 per share raising proceeds of US$74.9 million. The shares include 1,575,000 shares of common stock sold pursuant to the over-allotment option granted by Neovasc to the underwriters, which was exercised in full. In addition, 1,660,000 shares of common stock were offered by certain directors, officers and employees of the Company.

Canaccord Genuity acted as lead manager for the offering.

Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include the Tiara technology in development for the transcatheter treatment of mitral valve disease, the Reducer for the treatment of refractory angina and a line of advanced biological tissue products called Peripatch that are used as key components in third-party medical products including transcatheter heart valves.